Follow The Filings

BIIB Biogen

Health Care, filed as BIOGEN INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 3

  • 7 Owners
  • #220
  • Max 4.2%
  • Master 0.01%
  • $177M
  • 1 new 2 reduce 1 exit 3 small

In 2026 Q2 Farallon Capital Management opened a position in Biogen, Hillman Capital Management and Samantha McLemore trimmed, and Glenview Capital Management sold out.

Who owns this now

Largest portfolio weights among holders, up to 4.2% (Palo Alto Investors). Not free-float ownership.

  1. Palo Alto Investors Reduce 4.2%
  2. Hillman Capital Management Reduce 3.8%
  3. Samantha Mclemore Reduce 2.0%
  4. Michael Krensavage 1.6%
  5. Sarah Ketterer Reduce 0.65%
  6. Farallon Capital Management New 0.07%

Who owns BIIB

Sorted by value, long equity only, as of 2026 Q2.

History
Samantha Mclemore, Patient Capital Management 2.0%, was 2.6% Reduce −25.3% 283,697 $61M History
Sarah Ketterer, Causeway Capital Management 0.65% Small trim −0.9% 278,283 $60M History
Palo Alto Investors 4.2% Small trim −0.3% 140,279 $30M History
Farallon Capital Management 0.07% New 0.07% 71,000 $15M History
Hillman Capital Management 3.8%, was 3.8% Reduce −18.8% 23,993 $5.2M History
Michael Krensavage, Krensavage Asset Management 1.6% Hold 20,000 $4.3M History
Murray Stahl, Horizon Kinetics Asset Management 0.01% Small trim −4.6% 2,726 $589K History
Glenview Capital Management exited 2026 Q2 Last 2026 Q1 0.26% Exit −0.26% 57,019 $10M History

7 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by BIIB's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BIIB insider trades
  • $585 bought by 1 insider
  • None no sales outside a trading plan
  • $905K sold by 2 insiders under 10b5-1 plans
  1. Lloyd Minor Director
    Planned sale
    $240K 1,186 shares at $202.15 31% of stake
    Traded Aug 3–4 Filed Aug 5
    ↗
  2. Nicole Murphy Head of Pharm Ops and Tech
    Buy
    $585 3 shares at $195.04 +<0.1% to stake
    Traded Feb 12 Filed Feb 17
    ↗
  3. Priya Singhal Head of Development
    Planned sale
    $532K 2,660 shares at $199.83 25% of stake
    Traded Feb 9 Filed Feb 10
    ↗
  4. Priya Singhal Head of Development
    Planned sale
    $134K 748 shares at $179.30 11% of stake
    Traded Feb 2 Filed Feb 3
    ↗

Also filed in the last 12 months, not counted as buying or selling: 33 option exercises, 32 share withholdings for taxes, and 9 stock grants.

Congress

5 members of Congress traded BIIB in the last three years: 8 buys and 4 sales. 4 members listed it in 2025 annual reports.

All Congress trades
  1. Maria Elvira Salazar R-FL-27 Partial sale $1K–$15K Sep 24 filed Oct 7
  2. Kevin Hern R-OK-1 Sell $1K–$15K Aug 18 filed Sep 1
  3. Alan Armstrong R-OK Buy $1K–$15K Mar 27 filed Jul 21
  4. Maria Elvira Salazar R-FL-27 Sell $15K–$50K Jun 2 filed Jul 7
  5. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Jun 5 filed Jul 2
  6. Maria Elvira Salazar R-FL-27 Buy $1K–$15K May 12 filed Jun 8

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02 Filing Doc
8-K/A 9.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 1.01,2.01,2.03,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13D — Filing Doc
8-K 2.02 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02 Filing Doc

Source: SEC EDGAR submissions, updated 2 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $9.84B $9.68B $9.89B
Net income $1.16B $1.63B $1.29B
Net margin * 11.8% 16.9% 13.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $6.86B $7.46B $8.97B
Total non-current assets * $19.99B $20.59B $20.47B
Total assets $26.84B $28.05B $29.44B
Total current liabilities $3.43B $5.53B $3.35B
Total non-current liabilities * $8.61B $5.8B $7.83B
Total equity $14.8B — —

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $1.55B $2.88B $2.2B
Cash from investing -$4.1B -$0.799B -$1.37B
Cash from financing $149.3M -$683.5M -$301.9M
Net change in cash * -$2.4B $1.39B $0.532B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.